1-[5-chloro-2-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea | 697278-53-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[5-chloro-2-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea
• 英文别名: 1-[5-Chloro-2-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea；1-[5-chloro-2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]urea
• CAS: 697278-53-8
• 化学式: C₁₆H₁₀ClF₃N₄O₃
• 分子量: 398.729
• InChiKey: JHUBTWRPSAEQAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  91.8
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氨基-4-氯苯腈 在 盐酸羟胺 、 水 、 sodium ethanolate 、 potassium hydrogencarbonate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 42.0h， 生成 1-[5-chloro-2-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea
  参考文献：
  名称：

  [EN] ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE
  [FR] NOUVEAUX DERIVES D'ACIDE ARYL UREIDO BENZOIQUE ET LEUR UTILISATION

  摘要：

  公开号：

  WO2004046090A3

文献信息

• [EN] ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES<br/>[FR] OUVREURS DU CANAL ERG DESTINES AU TRAITEMENT DE MALADIES NEURONALES LIEES A L'HYPEREXCITABILITE
  申请人：POSEIDON PHARMACEUTICALS AS

  公开号：WO2005023238A1

  公开（公告）日：2005-03-17

  This invention relates to the use of ERG channel openers for the treatment of hyperexcitability-related neuronal diseases, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.

  本发明涉及使用ERG通道开放剂治疗与高兴奋性有关的神经疾病，以及使用特定化合物进行此类治疗。在另一个方面，本发明提供了新型化合物，可用作ERG通道开放剂。
• [EN] ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS<br/>[FR] SUBSTANCES D'OUVERTURE DES CANAUX ERG POUR LE TRAITEMENT D'ARYTHMIES CARDIAQUES
  申请人：POSEIDON PHARMACEUTICALS AS

  公开号：WO2005023237A1

  公开（公告）日：2005-03-17

  This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.

  本发明涉及使用ERG通道开放剂治疗心律失常，以及使用特定化合物进行此类治疗。在另一个方面，本发明提供了用作ERG通道开放剂的新化合物。
• Novel aryl ureido benzoic acid derivatives and their use
  申请人：Valgeirsson Jon

  公开号：US20060069255A1

  公开（公告）日：2006-03-30

  This invention relates to novel aryl ureido benzoic acid derivatives useful as selective and non-competitive antagonists of the ionotropic GluR5 receptor. Due to their biological activity, the aryl ureido derivatives of the invention are considered useful for treating diseases that are responsive to modulation of an aspartate or a glutamate receptor. Moreover the invention provides chemical compounds for use according to the invention, as well as pharmaceutical compositions comprising the chemical compounds, and methods of treating diseases or disorders or conditions responsive to modulation of an aspartate or a glutamate receptor.

  本发明涉及新型芳基脲基苯甲酸衍生物，可用作离子型GluR5受体的选择性和非竞争性拮抗剂。由于它们的生物活性，本发明的芳基脲基衍生物被认为对于治疗对天冬氨酸或谷氨酸受体调节敏感的疾病有用。此外，本发明提供了用于本发明的化学化合物，以及包含该化学化合物的药物组合物和治疗对天冬氨酸或谷氨酸受体调节敏感的疾病、障碍或状况的方法。
• Erg channel openers for the treatment of cardiac arrhythmias
  申请人：Olesen Peter Soren

  公开号：US20060281794A1

  公开（公告）日：2006-12-14

  This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.

  本发明涉及使用ERG通道开放剂治疗心律失常，并涉及使用特定化合物进行此类治疗。在另一个方面，本发明提供了新的化合物，可用作ERG通道开放剂。
• Aryl ureido benzoic acid derivatives and their use
  申请人：Neurosearch

  公开号：US07521480B2

  公开（公告）日：2009-04-21

  This invention relates to novel aryl ureido benzoic acid derivatives useful as selective and non-competitive antagonists of the ionotropic GluR5 receptor. Due to their biological activity, the aryl ureido derivatives of the invention are considered useful for treating diseases that are responsive to modulation of an aspartate or a glutamate receptor. Moreover the invention provides chemical compounds for use according to the invention, as well as pharmaceutical compositions comprising the chemical compounds, and methods of treating diseases or disorders or conditions responsive to modulation of an aspartate or a glutamate receptor.

  本发明涉及一种新型芳基脲基苯甲酸衍生物，可用作离子型GluR5受体的选择性和非竞争性拮抗剂。由于它们的生物活性，本发明的芳基脲基衍生物被认为对于治疗对天冬氨酸或谷氨酸受体调节敏感的疾病有用。此外，本发明还提供了用于本发明的化学化合物，以及包含该化学化合物的制药组合物和治疗对天冬氨酸或谷氨酸受体调节敏感的疾病、疾病或疾病的方法。